FDA
-
-
-
-
-
-
-
Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease
-
-
-
-
-
-
-
Agios submits application for accelerated approval of mitapivat in sickle cell
-
-
-
-
-
-
-
Stifel: 'we think FULC as a soon-to-be ph3 SCD company is significantly under-appreciated'
-
-
-
-
-
-
-
Agios outlines 2026 milestones for rare disease drug portfolio
-
-
-
-
-
-
-
Agios awaits FDA decision on mitapivat for thalassemia treatment
-
-
-
-
-
-
-
Agios to Present New Mitapivat Data in Rare Blood Disorders at 67th ASH Annual Meeting and Exposition
-
-
-
-
-
-
-
Agios Pharma (AGIO) PT Lowered to $51 at BofA Securities
-
328,148 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

